Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma

Journal of Cellular Biochemistry

Volumn 104, Issue 3, 2008, Pages 745-755

  Liu, Liyun ^a,b   Wang, Jianing ^a,b   Liu, Bo ^c   Dai, Songwei ^a,b   Wang, Xiaomin ^a,b   Chen, Junzhou ^c   Huang, Lingyun ^a,b   Xiao, Xueyuan ^a,b   He, Dacheng ^a,b  

^a BEIJING NORMAL UNIVERSITY   (China)

^b Universities' Confederated Institute of Proteomics   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CC; ELISA; SELDI TOF MS; TTR

Indexed keywords

CA 19-9 ANTIGEN; PREALBUMIN;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATOBILIARY DISEASE; HUMAN; IMMUNOPRECIPITATION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CA-19-9 ANTIGEN; CASE-CONTROL STUDIES; CHOLANGIOCARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PREALBUMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 45149123775     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21661     Document Type: Article

References (35)

1. Akdogan M, Parlak E, Kayhan B, Balk M, Saydam G, Sahin B. 2003. Are serum and biliary carcinoembryonic antigen and carbohydrate antigenl 9-9determinations reliable for differentiation between benign and malignant biliary disease? Turk J Gastroenterol 14:181-184.
2. Altland K, Winter P. 2003. Polyacrylamide gel electrophoresis followed by sodium dodecyl sulfate gradient polyacrylamide gel electrophoresis for the study of the dimer to monomer transition of human transthyretin. Electrophoresis 24:2265-2271.
3. Amareth L, Tatiana P, Mark EM, Lawreen HC, Martha S, Cathrrine EC. 2003. Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis. Protein Sci 12:1775-1785.
4. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST. 2003. Differential effects of prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci USA 100:1751.
5. Bergen HR, Zeldenrust SR, Butz ML, Snow DS, Dyck PJ, Dyck PJ, Klein CJ, O'Brien JF, Thibodeau SN, Muddiman DC. 2004. Identification of transthyretin variants by sequential proteomic and genomic analysis. Clin Chem 50:1544-1552.
6. Bjornsson E, Kilander A, Olsson R. 1999. CA19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 19:501-508.
7. Campbell WL, Ferris JV, Holbert BL, Thaete FL, Baron RL. 1989. Biliary tract carcinoma complicating primary sclerosing cholangitis: Evaluation with CT, cholangiography, US, and MR imaging. Radiology 207:41-50.
8. Ferlini A, Fini S, Salvi F, Patrosso MC, Vezzoni P, Forabosco A. 1992. Molecular strategies in genetic diagnosis of transthyretin-related hereditary amyloidosis. FASEB J 6:2864-2866.
9. Fung ET, Yip TT, Lomas L, Wang Z, Yip C, Meng XY, Lin S, Zhang F, Zhang Z, Chan DW, Weinberger SR. 2005. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 115:783-789.
10. Geho DH, Liotta LA, Petricoin EF, Zhao W, Araujo RP. 2006. The amplified peptidome: The new treasure chest of candidate biomarkers. Curr Opin Chem Biol 10:50-55.
11. Gericke B, Raila J, Sehouli J, Haebel S, Könsgen D, Mustea A, Schweigert FJ. 2005. Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer 5:133.
12. Horsmans Y, Laka A, van Beers BE, Descamps C, Gigot JF, Geubel AP. 1997. Hepatobiliary cystadenocarcinoma without ovarian stroma and normal CA19-9 levels. Unusually prolonged evolution. Dig Dis Sci 42:1406-1408.
13. Imanishi T. 1981. Clinical and experimental studies on the profiles of serum proteins in acute hepatic injury. Gastroenterol Jpn 16:493-505.
14. Ingenbleek Y, Young V. 1994. Transthyretin (prealbumin) in health and disease: Nutritional implications. Annu Rev Nutr 14:495-533.
15. Jacobsson B, Collins VP, Grimelius L, Pettersson T, Sandstedt B, Carlstrom A. 1989. Transthyretin immunoreactivity in human and porcine liver, choroid plexus, and pancreatic islets. J Histochem Cytochem 37:31-37.
16. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. 2005. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5:4589-4596.
17. Lim A, Sengupta S, McComb ME, Théberge R, Wilson WG, Costello CE, Jacobsen DW. 2003. In vitro and in vivo interactions of homocysteine with human plasma transthyretin. J Biol Chem 278:49707-49713.
18. Lin CL, Changchien CS, Chen YS. 1997. Mirizzi's syndrome with a high CA 19-9level mimicking cholangiocarcinoma. Am J Gastroenterol 92:2309-2310.
19. Liotta LA, Petricoin EF. 2006. Serum peptidome for cancer detection: Spinning biologic trash into diagnostic gold. J Clin Invest 116:26-30.
20. Lowenthal MS, Mehta AI, Frogale K, Bandle RW, Araujo RP, Hood BL, Veenstra TD, Conrads TP, Goldsmith P, Fishman D, Petricoin EF, Liotta LA. 2005. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 51(10):1933-1945.
21. Marten NW, Sladek FM, Straus DS. 1996. Effect of dietary protein restriction on liver transcription factors. Biochem J 317(Pt 2):361-370.
22. Menard C, Johann D, Lowenthal M, Muanza T, Sproull M, Ross S, Gulley J, Petricoin E, Coleman CN, Whiteley G, Liotta L, Camphausen K. 2006. Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res 66:1844-1850.
23. Minato H, Nakanuma Y, Terada T. 1996. Expression of blood grouprelated antigens in cholangiocarcinoma in relation to non-neoplastic bile ducts. Histopathology 28:411-419.
24. Munro NP, Cairns DA, Clarke P, Rogers M, Stanley AJ, Barrett JH, Harnden P, Thompson D, Eardley I, Banks RE, Knowles MA. 2006. Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer 119:2642-2650.
25. Patel T. 2006. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 3:33-42.
26. Power DM, Elias NP, Richardson SJ, Mendes J, Soares CM, Santos CR. 2000. Evolution of the thyroid hormone-binding protein, transthyretin. Gen Comp Endocrinol 119:241-255.
27. Raghu P, Sivakumar B. 2004. Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: Implications in vitamin A homeostasis and transthyretin amyloidosis. Biochim Biophys Acta 1-9.
28. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. 1999. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: A practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 13:273-279.
29. Scarlett CJ, Saxby AJ, Nielsen A, Bell C, Samra JS, Hugh T, Baxter RC, Smith RC. 2006. Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Hepatology 44(3):658-666.
30. Schreiber G. 2002. The evolutionary and integrative roles of transthyretin in thyroid hormone homeostasis. J Endocrinol 175:61-73.
31. Shaib Y, El-Serag HB. 2004. The epidemiology of cholangiocarcinoma. Semin Liver Dis 24:115-125.
32. Technical resource. 2005. Process stained polyacrylamide gel pieces for mass spectrometry.
33. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJ, Johnson PJ, Martin A. 2006. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 94:1898-1905.
34. Xiao X, Zhao X, Liu J, Guo F, Liu D, He D. 2004. Discovery of laryngeal carcinoma by serum proteomic pattern analysis. Sci Chin 47:219-223.
35. Yu Y, Chen S, Wang LS, Chen WL, Guo WJ, Yan H, Zhang WH, Peng CH, Zhang SD, Li HW, Chen GQ. 2005. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology 68:79-86.